03.06.2022 - SOUTH SAN FRANCISCO, Calif., June 03, 2022 (GLOBE NEWSWIRE) - Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that additional results from a new analysis from REDWOOD-HCM (Randomized Evaluation of Dosing With CK-274 in Obstructive . Seite 1
23.05.2022 - Data from Up to Six Months of Treatment with Aficamten Show Significant and Sustained Reductions in LVOT Gradients with Improvements in Functional Class, Symptoms, and Biomarkers Analyses from GALACTIC-HF Show Patients with Low Blood Pressure Have . Seite 1
Data from Up to Six Months of Treatment with Aficamten Show Significant and Sustained Reductions in LVOT Gradients with Improvements in Functional Class,.
Initial Data from REDWOOD-HCM OLE, the Open Label Extension Study of Aficamten, to be Presented at Heart Failure 2022 on May 23, 2022 Continued Launch.